Evaxion A/S (EVAX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EVAX currently has 70.1M outstanding shares. with significant dilution risk as 49.2M authorized shares could dilute existing holders by 70.1%. The company has significantly diluted shareholders by 346.54% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 01, 2025 |
20-F filing | 70.1M shares outstanding |
70M | 49M |
| Mar 13, 2025 |
F-3 filing: Evaxion Biotech A/S intends to offer and sell up to $50,000,000 of its ordinary shares, including ordinary shares represented by American Depositary Shares, from time to time in one or more offerings under a new shelf registration statement. |
240M | 49M |
| Nov 18, 2024 |
F-1 filing: This F-1 filing describes an offering of up to 5,252,100 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 5,252,100 ADSs, with Lake Street Capital Markets, LLC acting as the exclusive placement agent. |
54M | 49M |
| May 06, 2024 |
F-1 filing: The selling shareholders are offering on a resale basis an aggregate of up to 19,453,796 ordinary shares represented by 1,945,379 ADSs. |
54M | 39M |
| Mar 26, 2024 |
20-F filing | 37.9M shares outstanding |
38M | 19M |
| Jan 12, 2024 |
F-1 filing: This F-1 filing registers ordinary shares, warrants, and pre-funded warrants. The company intends to use the net proceeds of this offering to advance our preclinical and clinical pipeline, and for continuing operating expenses and working capital. |
38M | 19M |
| Aug 25, 2023 |
POS AM filing: This POS AM filing registers for resale by Lincoln Park Capital Fund, LLC up to 4,649,250 ADSs representing ordinary shares, consisting of commitment shares and additional shares that may be issued under a purchase agreement, with potential gross proceeds of up to $40,000,000. |
28M | 5.9M |
| Apr 28, 2023 |
20-F filing | 24.1M shares outstanding |
24M | 11M |
| Jul 07, 2022 |
F-1 filing: This F-1 filing describes an offering of American Depositary Shares (ADSs) by Lincoln Park, consisting of 428,572 commitment shares and up to 4,220,678 ordinary shares, with the company potentially receiving up to $40,000,000 in gross proceeds for working capital and general corporate purposes. |
24M | 11M |
| May 20, 2022 |
F-3 filing: Evaxion Biotech A/S may offer and sell up to $100,000,000 of its ordinary shares, including ordinary shares represented by American Depositary Shares. |
23M | 5.9M |
| Mar 31, 2022 |
20-F filing | 23.2M shares outstanding |
23M | 5.9M |
| Oct 26, 2021 |
F-1 filing: This F-1 filing describes the offering of 5,167,958 ADSs at an assumed price of $7.74 per ADS, with an option for underwriters to purchase an additional 775,193 ADSs. It also discusses the company's status as a foreign private issuer and emerging growth company, and the implications of these statuses on reporting obligations and investor protections. |
24M | 5.9M |
| Apr 07, 2021 |
20-F filing | 16.2M shares outstanding |
16M | 0 |